As the cleavage of APPs by α-secretase results in the generation of the extracellular P3 peptide and intracellular AICD fragments without Aβ deposition in the non-amyloidogenic pathway, increasing the activity of α-secretase has recently been considered as a therapeutic approach for the treatment of AD. This evidence concerns the gene CTSB and Alzheimer disease.